glp-1 news updates november 2025 trends 2025: real-world data, patient outcomes & future therapies GLP-1 Pipeline Update: November 2025

Why Sun Pharmas semaglutide approval matters in Indias weight loss drug market Besides Sun Pharma, a growing roster of Indian drugmakers is lining up cheaper generic versions of semaglutide ahead of the patent expiry in March 2026 to tap into demand Earlier today, Sun Pharmaceutical Industries said it had received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection, a glucagonlike peptide1 (GLP1) receptor agonist indicated for chronic weight management in adults

I don't know which B12 sort you have been injecting, but some people definately cannot handle cyanocobalamin

Kluijtmans LAJ, Boers GHJ, Stevens EMB, Renier WO, Kraus JP, Trijbels FJM, van den Heuvel LPWJ, Blom HJ: Defective cystathionine beta-synthase regulation by S-adenosyl-methionine in a partially pyridoxine responsive homocysteinuria patient

Green Tea Extract Antioxidant and wellness booster